Company intelligence / Profile preview
Hangzhou Hezheng Pharmaceutical
Hangzhou, Zhejiang, Chinacn.healzentx.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Hangzhou Hezheng Pharmaceutical is an innovative Chinese biotech/pharma company focused on developing novel small molecule drugs—especially PROTACs—for oncology indications. Its lead asset has reached Phase 3 for peripheral T-cell lymphoma. The pipeline includes multiple programs targeting kinases and apoptosis regulators relevant to hematological malignancies. The company has received national innovation awards in China for its R&D achievements. No commercialized products yet reported.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeProteolysis-targeting chimera therapy (PROTAC)Antibody-drug conjugateMolecular glue therapyChemical drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hangzhou Hezheng Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Hezheng Pharmaceutical.